So­bi rene­go­ti­ates nir­se­vimab deals, to pay $81M for US roy­al­ties and axe As­traZeneca agree­ment

So­bi has an­nounced two new up­dates that it said would “stream­line” pre­vi­ous arrange­ments re­lat­ed to nir­se­vimab and give the com­pa­ny more flex­i­bil­i­ty.

So­bi said Sun­day that it reached a new roy­al­ty agree­ment with Sanofi on net US sales of the RSV an­ti­body, cur­rent­ly brand­ed as Bey­for­tus in the re­gions where it is ap­proved. Ac­cord­ing to a com­pa­ny state­ment, So­bi will start out with a 25% roy­al­ty of all US sales, start­ing at launch and paid out every quar­ter. As part of the agree­ment, So­bi is pony­ing up $66 mil­lion to re­im­burse Sanofi for pre­vi­ous R&D ex­pens­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.